Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer
The purposes of this study are: * To determine the overall response rate of patients treated with at least 2 cycles of this regimen. * To determine the feasibility and toxicity of the combination of topotecan and docetaxel.
Checked against the public recordLast updated Aug 20, 2018 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Aultman Health Foundation
- Interventions being studied
- Drug: Intravenous Topotecan; Drug: Intravenous Docetaxel
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Recurred greater than 90 days after initial treatment * At least 1 measurable lesion * Only 1 prior chemotherapy * Must be over 18 years of age * ECOG performance status of 0 - 2 * Adequate hematologic, renal, and hepatic function Exclusion Criteria: * No prior use of topotecan, docetaxel, or irinotecan * No symptomatic brain metastases * History of cardiac arrhythmias, congestive heart failure, stroke, or embolic events * No prior investigational agents within 1 month prior * Lung cancer of mixed histology * Known uncontrolled seizure disorders
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Aultman HospitalCanton, Ohio
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 20, 2018. Always confirm current availability with the study team.